Prognostic value of S100A4 and Glypican-3 in hepatocellular carcinoma in cirrhotic HCV patients.
Cirrhotic
Glypican-3
HCV
Hepatocellular carcinoma
Prognosis, S100A4
Journal
Journal of the Egyptian National Cancer Institute
ISSN: 2589-0409
Titre abrégé: J Egypt Natl Canc Inst
Pays: England
ID NLM: 9424566
Informations de publication
Date de publication:
21 Aug 2023
21 Aug 2023
Historique:
received:
02
01
2023
accepted:
27
07
2023
medline:
22
8
2023
pubmed:
21
8
2023
entrez:
20
8
2023
Statut:
epublish
Résumé
Both S100A4 and Glypican-3 have been known to be engaged in HCC development and progression. This study aimed to evaluate both S100A4 and GPC3 expression in HCC tissues as a prognostic markers. Tissues from 70 patients of HCC in cirrhotic HCV patients were evaluated by immunohistochemistry using antibodies against SA100A4 and GPC3 and compared with tumor-adjacent tissue (controls). All cases were followed for 40 months. GPC3 was more expressed in HCC (79%) than S100A4 (21%). S100A4 was more significantly expressed in cases showing metastasis, microscopic vascular emboli, necrosis, and grade III tumors. There was no relationship between overall survival and both S100A4 and GPC3. The only significant independent predictor for recurrence was decompensation (OR 3.037), while metastasis was significantly predicted by S100A4 expression (OR 9.63) and necrosis (OR 8.33). S100A4 might be used as a prognostic marker for HCC, while GPC3 is a reliable marker of HCC diagnosis.
Identifiants
pubmed: 37599312
doi: 10.1186/s43046-023-00184-1
pii: 10.1186/s43046-023-00184-1
doi:
Substances chimiques
Glypicans
0
S100A4 protein, human
142662-27-9
S100 Calcium-Binding Protein A4
0
GPC3 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26Informations de copyright
© 2023. Egyptian National Cancer Institute.
Références
Global Burden of Disease Cancer C. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1(4):505–27. https://doi.org/10.1001/jamaoncol.2015.0735 .
doi: 10.1001/jamaoncol.2015.0735
Xiao W, Zhao W, Li L, Wu Q, Zhu L, Zhang Q, Dai W, Wang Y, Zhang B. Preliminary investigation of the role of BTB domain-containing 3 gene in the proliferation and metastasis of hepatocellular carcinoma. Oncology Lett. 2017;14(2):2505–10. https://doi.org/10.3892/ol.2017.6369 . (PMID: 28789460).
doi: 10.3892/ol.2017.6369
Shaker MK, Abdella HM, Khalifa MO, Dorry AKE. Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases. Liver Int. 2013;33(10):1601–6. https://doi.org/10.1111/liv.12209 . (PMID: 23714212).
doi: 10.1111/liv.12209
pubmed: 23714212
El-Bendary M, Nour D, Arafa M, Neamatallah M. Methylation of tumour suppressor genes RUNX3, RASSF1A and E-cadherin in HCV-related liver cirrhosis and hepatocellular carcinoma. Br J Biomed Sci. 2020;77(1):35–40. https://doi.org/10.1080/09674845.2019.1694123 . (PMID: 31790342).
doi: 10.1080/09674845.2019.1694123
pubmed: 31790342
Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, Cho JY, Yoo JE, Choi JS, Park YN. Human hepatocellular carcinomas with “stemness”-related marker expression: keratin 19 expression and a poor prognosis. Hepatology. 2011;54(5):1707–17. https://doi.org/10.1002/hep.24559 . (PMID: 22045674).
doi: 10.1002/hep.24559
pubmed: 22045674
Cui JF, Liu YK, Zhang LJ, Shen HL, Song HY, Dai Z, Yu YL, Zhang Y, Sun RX, Chen J, Tang ZY, Yang PY. Identification of metastasis candidate proteins among HCC cell lines by comparative proteome and biological function analysis of S100A4 in metastasis in vitro. Proteomics. 2006;6(22):5953–61. https://doi.org/10.1002/pmic.200500460 . (PMID: 17051636).
doi: 10.1002/pmic.200500460
pubmed: 17051636
Kim JK, Jung KH, Noh JH, Eun JW, Bae HJ, Xie HJ, Ahn YM, Ryu JC, Park WS, Lee JY, Nam SW. Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma. Int J Oncol. 2009;35(6):1257–64 (PMID: 19885547).
pubmed: 19885547
Haruyama Y, Kataoka H. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol. 2016;22(1):275–83. https://doi.org/10.3748/wjg.v22.i1.275 . (PMID: 26755876).
doi: 10.3748/wjg.v22.i1.275
pubmed: 26755876
pmcid: 4698492
Wu Y, Liu H, Ding H. GPC-3 in hepatocellular carcinoma: current perspectives. J Hepatocell Carcinoma. 2016;3:63–7. https://doi.org/10.2147/JHC.S116513jhc-3-063 . (PMID: 27878117).
doi: 10.2147/JHC.S116513jhc-3-063
pubmed: 27878117
pmcid: 5108608
EASL-EORTC clinical practice guidelines. management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–94 S0168-8278(11)00873-7. PMID: 22424438.
doi: 10.1016/j.jhep.2011.12.001
Neamatallah MA, El-Missiry MA, Said MMA, Elbendary M, Othman AI, Ammar OA. TP53 polymorphism as a risk factor for hepatocellular carcinoma in hepatitis C virus-infected Egyptian patients. Egypt J Basic Appl Sci. 2014;1(1):9–15. https://doi.org/10.1016/j.ejbas.2014.01.001 .
doi: 10.1016/j.ejbas.2014.01.001
Farid K, Elalfy H, El-Bendary M, Besheer T, El-Eraky A, Abdelbadie M, Elmokadem A, Moawad A, El-khair SA, Sakr S, El-Deek B, El-Morsy A, Elmorsy RA, Amer T, Abed S. Cardiopulmonary assessment of patients with unresectable hepatocellular carcinoma treated by transarterial chemoembolization. J Liver Transplant. 2022;5:100063. https://doi.org/10.1016/j.liver.2021.100063 .
doi: 10.1016/j.liver.2021.100063
Elalfy H, Besheer T, El-Maksoud M, Farid K, Elegezy M, El Nakib A, El-Aziz M, El-Khalek A, El-Morsy A, Elmokadem A. Monocyte/granulocyte to lymphocyte ratio and the MELD score as predictors for early recurrence of hepatocellular carcinoma after trans-arterial chemoembolization. Br J Biomed Sci. 2018;75(4):187–91. https://doi.org/10.1080/09674845.2018.1494769 . (PMID: 29991324).
doi: 10.1080/09674845.2018.1494769
pubmed: 29991324
Farid K, Elalfy H, Abo El-khair SM, Elgamal H, Besheer T, Elmokadem A, Shabana W, Abed S, Elegezy M, El-khalek AA, El-Morsy A, Negm A, Elsamanoudy AZ, El deek B, Amer T, El-Bendary M. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients. Exp Rev Gastroenterol Hepatol. 2020; 14(12): 1203-1214. https://doi.org/10.1080/17474124.2020.1823215 .
Besheer T, El-Bendary M, Elalfy H, Abd El-Maksoud M, Salah M, Zalata K, Elkashef W, Elshahawy H, Raafat D, Elemshaty W. Prediction of fibrosis progression rate in patients with chronic hepatitis C genotype 4: role of cirrhosis risk score and host factors. J Interferon Cytokine Res. 2017;37(3):97–102. https://doi.org/10.1089/jir.2016.0111 . (PMID: 28068153).
doi: 10.1089/jir.2016.0111
pubmed: 28068153
Besheer T, Arafa M, El-Maksoud MA, Elalfy H, Hasson A, Zalata K, Elkashef W, Elshahawy H, Raafat D, Elemshaty W. Diagnosis of cirrhosis in patients with chronic hepatitis C genotype 4: role of ABCB11 genotype polymorphism and plasma bile acid levels. Turk J Gastroenterol. 2018;29(3):299. https://doi.org/10.5152/tjg.2018.17570 . (PMID: 29755014).
doi: 10.5152/tjg.2018.17570
pubmed: 29755014
pmcid: 6284664
Neamatallah M, El-Bendary M, Elalfy H, Besheer T, El-Maksoud MA, Elhammady D, Abed S, Elegezy M, Kandeel L, Eldeib D. Impact of toll-like receptors 2 (TLR2) and TLR 4 gene variations on HCV susceptibility, response to treatment and development of hepatocellular carcinoma in cirrhotic HCV patients. Immunol Investig. 2019: 1-15. https://doi.org/10.1080/08820139.2019.1673772 PMID: 29755014.
Abdel-Azziz MY, Zalata KR, El-Bendary MM. Insulin resistance and liver fibrosis progression in patients with chronic hepatitis C virus infection. Arab J Gastroenterol. 2010;11(1):30–4. https://doi.org/10.1016/j.ajg.2010.01.004 .
doi: 10.1016/j.ajg.2010.01.004
Staib F, Krupp M, Maass T, Itzel T, Weinmann A, Lee JS, Schmidt B, Muller M, Thorgeirsson SS, Galle PR, Teufel A. Cell MinerHCC: a microarray-based expression database for hepatocellular carcinoma cell lines. Liver Int. 2013;34(4):621–31. https://doi.org/10.1111/liv.12292 . (PMID: 24016071).
doi: 10.1111/liv.12292
pubmed: 24016071
pmcid: 6993137
Yan X-L, Jia Y-L, Chen L, Zeng Q, Zhou J-N, Fu C-J, Chen H-X, Yuan H-F, Li Z-W, Shi L, Xu Y-C, Wang J-X, Zhang X-M, He L-J, Zhai C, Yue W, Pei X-T. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology. 2013;57(6):2274–86. https://doi.org/10.1002/hep.26257 . (PMID: 23316018).
doi: 10.1002/hep.26257
pubmed: 23316018
Liu Z, Liu H, Pan H, Du Q, Liang J. Clinicopathological significance of S100A4 expression in human hepatocellular carcinoma. J Int Med Res. 2013;41(2):457–62. https://doi.org/10.1177/0300060513478086 . (PMID: 23781010. DOI: 41/2/457 [pii]).
doi: 10.1177/0300060513478086
pubmed: 23781010
Cho YG, Kim CJ, Kim SY, Nam SW, Lee SH, Yoo NJ, Lee JY, Park WS. Overexpression of S100A4 is closely associated with the progression of gastric cancers and hepatocellular carcinomas. Cancer Res. 2004;64(7):1166. https://doi.org/10.1034/j.1600-0463.2003.1110502 . (PMID:12887505).
doi: 10.1034/j.1600-0463.2003.1110502
Abdel Allah HMM, Zahran WE, El-Masry SA, El-Bendary M, Soliman AF. Association of MTHFR and TYMS gene polymorphisms with the susceptibility to HCC in Egyptian HCV cirrhotic patients. Clin Exp Med. 2021. https://doi.org/10.1007/s10238-021-00747-3 . (PMID: 34297238).
doi: 10.1007/s10238-021-00747-3
pubmed: 34297238
Elbaz T, Waked I, El-Akel W, Shaker MK, Abdelaziz AO, Yousif M, El-Bendary M, Zaky S, AbdAllah M, Hassany M, Esmat G, Doss W. Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. Exp Rev Anti-infective Ther. 2021: https://doi.org/10.1080/14787210.2021.1951230 . PMID: 34253123.
Cantarini MC, Trevisani F, Morselli-Labate AM, Rapaccini G, Farinati F, Del Poggio P, Di Nolfo MA, Benvegnu L, Zoli M, Borzio F, Bernardi M. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol. 2006;101(1):91–8. https://doi.org/10.1111/j.1572-0241.2006.00364.x . (PMID: 16405539 DOI: AJG364 [pii]).
doi: 10.1111/j.1572-0241.2006.00364.x
pubmed: 16405539
Sinn DH, Gwak GY, Cho J, Paik SW, Yoo BC. Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort. PLoS One. 2015;9(11):e112184. https://doi.org/10.1371/journal.pone.0112184 . (PMID: 25372403. PONE-D-14-28985 [pii]).
doi: 10.1371/journal.pone.0112184
Helfman DM, Kim EJ, Lukanidin E, Grigorian M. The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer. 2005;92(11):1955–8. https://doi.org/10.1038/sj.bjc.6602613 . (PMID: 15900299).
doi: 10.1038/sj.bjc.6602613
pubmed: 15900299
pmcid: 2361793
Pedersen KB, Nesland JM, Fodstad Ø, Mælandsmo GM. Expression of S100A4, E-cadherin, α- and β-catenin in breast cancer biopsies. Br J Cancer. 2002;87(11):1281–6. https://doi.org/10.1038/sj.bjc.6600624 . (PMID: 12439718).
doi: 10.1038/sj.bjc.6600624
pubmed: 12439718
pmcid: 2408909
Xiao WK, Qi CY, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis. BMC Cancer. 2014;14:104. https://doi.org/10.1186/1471-2407-14-104 . (PMID: 24548704: 1471-2407-14-104).
doi: 10.1186/1471-2407-14-104
pubmed: 24548704
pmcid: 3984430